Silencing Cancer's Amplifier: RNA-Targeting Therapeutics to Disrupt MYC-Driven Tumor Growth
This technology introduces novel antisense oligonucleotide inhibitors targeting MYC-bound enhancer RNA, specifically GREB1 (MERG1), to effectively suppress cancer cell proliferation across multiple malignancies by modulating gene expression pathways critical for oncogenesis.
Description
The transcription factor MYC is one of the most frequently dysregulated oncogenes in human cancer, yet it has long been considered undruggable due to the lack of targetable binding pockets and the toxicity associated with direct inhibition. This invention takes an indirect approach by targeting MERG1, a MYC-bound enhancer RNA that functions as a critical co-activator of GREB1 transcription. MERG1 physically interacts with MYC protein within the cell nucleus and enhances MYC's chromatin occupancy at the GREB1 promoter, thereby promoting epigenetic activation and amplifying GREB1 expression specifically in cancer cells. Importantly, this enhancer-promoter interaction is absent in normal breast epithelial cells, suggesting a cancer-specific vulnerability. The inhibitors consist of antisense oligonucleotides (ASOs) designed to knock down MERG1 RNA. When delivered via nanoparticle carriers, these ASOs suppress GREB1 expression, induce cell cycle arrest, reduce cancer cell proliferation, and significantly inhibit tumor growth in preclinical xenograft models, without apparent systemic toxicity. The platform is applicable across multiple cancer types where MERG1 and GREB1 are co-expressed and correlated with poor patient outcomes.Applications
- Therapeutic intervention in solid tumors where MYC-driven transcriptional dysregulation is a contributing factor, including breast, lung, ovarian, and pancreatic cancers.- Adjunct cancer therapies aiming to enhance the efficacy of existing treatments by targeting enhancer RNA-mediated oncogenic pathways.
- Development of personalized medicine approaches wherein patients with MYC-associated cancers can receive tailored antisense oligonucleotide treatments targeting their specific enhancer RNA profiles.
- Research tools for studying the functional role of MYC-bound enhancer RNAs in cancer progression and transcriptional regulation.
- Potential integration into combination therapies to reduce tumor resistance and improve clinical outcomes by mitigating MYC-driven transcriptional activation.
Advantages
- Specificity: The antisense oligonucleotides are designed to precisely target GREB1 (MERG1) enhancer RNA, minimizing off-target effects and enhancing treatment safety.- Novel Mechanism of Action: By targeting enhancer RNA rather than protein-coding sequences or MYC itself, this technology offers a distinct therapeutic pathway that circumvents challenges associated with direct MYC inhibition.
- Broad Applicability: The approach is applicable to multiple cancer types where MYC and its associated enhancer RNAs drive tumor progression, demonstrating versatility in clinical use.
- Potential to Overcome Resistance: Interrupting enhancer RNA function may reduce oncogenic signaling redundancy, thereby improving responsiveness to therapies and overcoming resistance mechanisms.
- Supportive Experimental Validation: The technology is underpinned by experimental data demonstrating effective inhibition of cancer cell proliferation, substantiating its therapeutic potential.